Literature DB >> 9684757

Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.

E Pósán1, G Ujj, A Kiss, B Telek, K Rák, M Udvardy.   

Abstract

Because platelets interact with fibrinolysis in a complex manner, it can be expected that with abnormal platelet numbers and quality this interference can be even more profound. The aim of this work was to study the lysis-resistance of platelet-rich clots in diseases with high platelet counts: polycythemia vera (PV), essential thrombocythemia (ET) and to make comparison with polyglobulia (PG). Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were analyzed by an in vitro clot lysis test. Plasminogen activator inhibitor-1 (PAI-1) activity was measured in plasma and in the supernatants of the washed and gel-filtered platelets after activation by thrombin. The lysis showed decreased speed of PPP-clots in PV and ET. This phenomenon was even more marked in PRP-clots from PV and ET, but further increased lysis resistance after retraction was not observed in PV and ET, most likely due to abnormal platelet functions. Our results suggest that the fibrinolytic activity is reduced in PV and ET, and may play a role both in the increased aptitude for venous thrombosis and in the arterial complications. These are partly caused by higher plasmatic PAI-1 activity as well as by more active platelet PAI-1. The PAI-1 activity was significantly higher in the supernatants of the washed and gel-filtered platelets of PV after activation by thrombin compared with controls. Other factors might have influenced the reduced fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684757     DOI: 10.1016/s0049-3848(98)00005-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.

Authors:  S L Senno; L Pechet
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

2.  JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Authors:  Zuzanna Kanduła; Michał Janowski; Barbara Więckowska; Edyta Paczkowska; Krzysztof Lewandowski
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-15       Impact factor: 4.322

3.  Prevalence of venous thromboembolism in patients with secondary polycythemia.

Authors:  Omar Nadeem; Jiang Gui; Deborah L Ornstein
Journal:  Clin Appl Thromb Hemost       Date:  2012-09-23       Impact factor: 2.389

Review 4.  Biophysical Mechanisms Mediating Fibrin Fiber Lysis.

Authors:  Nathan E Hudson
Journal:  Biomed Res Int       Date:  2017-05-28       Impact factor: 3.411

5.  JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.

Authors:  Alexandra Wolf; René Eulenfeld; Karoline Gäbler; Catherine Rolvering; Serge Haan; Iris Behrmann; Bernd Denecke; Claude Haan; Fred Schaper
Journal:  JAKSTAT       Date:  2013-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.